AbbVie expands siRNA push with $335m ADARx deal
AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
Pharma faces 30-day deadline under Trump’s pricing order
US President Donald Trump has signed an executive order aimed at reducing prescription drug prices by linking them to what…
-
Trump to sign order tying US drug prices to global rates
In a renewed push to overhaul pharmaceutical pricing in the US, President Donald Trump announced he will sign an executive…
-
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
-
Merck KGaA strikes $3.9bn deal for SpringWorks
Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire…
-
Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an…
-
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp,…
-
Boehringer to expand oncology presence with $572m Tessellate Bio deal
Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours…
-
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company…
-
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical…